雷珠单抗与全视网膜光凝治疗增殖性糖尿病视网膜病变:基线特征是否影响治疗选择
该研究基于DRCR.net Protocol S,分析增殖性糖尿病视网膜病变患眼中基线特征是否影响雷珠单抗相对全视网膜光凝(PRP)的获益。结果显示,在25项特征中没有任何一项显示PRP结局优于雷珠单抗;2年内雷珠单抗在视力变化和视力损害性中心型糖尿病黄斑水肿发生方面均优于PRP(P < 0.001)。
要点
- 25项基线特征中无一项显示PRP结局优于雷珠单抗。
- 2年内雷珠单抗在视力变化及视力损害性中心型DME发生上优于PRP(P < 0.001)。
- 部分特征(如平均动脉压较高)下雷珠单抗的相对获益似乎更大,属探索性分析。
核心结论
- 在增殖性糖尿病视网膜病变中,未发现任何基线特征下PRP结局优于雷珠单抗。
- 探索性分析进一步支持雷珠单抗可作为PRP在2年内的合理替代方案。
研究设计与样本
- 基于DRCR.net Protocol S的随机对照研究分析,纳入增殖性糖尿病视网膜病变、视力20/320或更好且既往未接受PRP的患眼。
- 患眼随机分配至PRP或玻璃体腔注射0.5 mg雷珠单抗。
主要发现
- 雷珠单抗在2年视力变化和视力损害性中心型糖尿病黄斑水肿发生方面优于PRP(P < 0.001)。
- 25项特征中无一项显示PRP组结局优于雷珠单抗组。
- 视力变化方面,雷珠单抗相对PRP的获益在平均动脉压较高(P = 0.03)、既往无局灶/格栅激光(P = 0.03)、临床检查见视盘及其他部位新生血管(P = 0.04)、照片显示更晚期增殖性糖尿病视网膜病变(P = 0.02)者中似乎更大。
- 视力损害性中心型糖尿病黄斑水肿方面,雷珠单抗相对PRP的获益在非白人参与者(P = 0.01)和平均动脉压较高者(P = 0.01)中似乎更大。
关键数值与推荐
- 视力损害性中心型糖尿病黄斑水肿与视力变化的比较均报告P < 0.001,支持雷珠单抗优于PRP。
- 各亚组交互作用P值范围为0.01至0.04,均为探索性分析。
临床怎么用
- 对增殖性糖尿病视网膜病变、视力20/320或更好且未接受过PRP的患眼,可考虑雷珠单抗作为PRP的替代方案。
- 基线特征不能用于筛选PRP优于雷珠单抗的患者,治疗选择需结合其他因素个体化。
局限性
- 亚组比较为探索性分析,交互作用P值未校正多重比较,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Among eyes with proliferative diabetic retinopathy, identify whether baseline characteristics impact the benefit of ranibizumab over panretinal photocoagulation (PRP) in DRCR.net Protocol S. METHODS: Participants had proliferative diabetic retinopathy, visual acuity of 20/320 or better, and no previous PRP. Eyes were randomized to PRP or intravitreous 0.5-mg ranibizumab. RESULTS: Ranibizumab was superior to PRP for change in visual acuity and development of vision-impairing central-involved diabetic macular edema over 2 years (P < 0.001). Among 25 characteristics, there were none in which participants assigned to PRP had superior outcomes relative to ranibizumab-assigned participants. The relative benefit of ranibizumab over PRP for change in visual acuity seemed greater in participants with higher mean arterial pressure (P = 0.03), without previous focal/grid laser (P = 0.03), with neovascularization of the disk and elsewhere on clinical examination (P = 0.04), and with more advanced proliferative diabetic retinopathy on photographs (P = 0.02). For development of vision-impairing central-involved diabetic macular edema, the relative benefit of ranibizumab over PRP seemed greater among nonwhite participants (P = 0.01) and those with higher mean arterial pressure (P = 0.01). CONCLUSION: There were no characteristics identified in which outcomes were superior with PRP compared with ranibizumab. These exploratory analyses provide additional support that ranibizumab may be a reasonable alternative to PRP for proliferative diabetic retinopathy over a 2-year period.
引用
- Bressler SB, Beaulieu WT, Glassman AR, et al. PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment? Retina. 2019. PMID: 30807516. doi:10.1097/IAE.0000000000002377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。